CAMBRIDGE, Mass.--(BUSINESS WIRE)--May. 14, 2009--
Alkermes, Inc. (NASDAQ: ALKS) will host a conference call at 4:30 p.m.
ET on Thursday, May 21, 2009, to discuss the company’s financial results
for the fiscal year ended March 31, 2009. Management will review the
results and provide financial expectations for fiscal year 2010.
The conference call will be webcast on the investor relations section of
Alkermes’ website at www.alkermes.com
or may be accessed by dialing 1-866-256-9239 for domestic callers and
1-703-639-1213 for international callers. The conference call ID number
is 1360066.
A replay of the conference call will be available from 7:30 p.m. ET on
Thursday, May 21, 2009, through 5:00 p.m. ET on Thursday, May 28, 2009,
and may be accessed by visiting Alkermes’ website or by dialing
1-888-266-2081 for domestic callers and 1-703-925-2533 for international
callers. The replay access code is 1360066.
About Alkermes
Alkermes, Inc. is a fully integrated biotechnology company committed to
developing innovative medicines to improve patients' lives. Alkermes
developed, manufactures and commercializes VIVITROL® for
alcohol dependence and manufactures RISPERDAL® CONSTA® for
schizophrenia. Alkermes' robust pipeline includes extended-release
injectable, pulmonary and oral products for the treatment of prevalent,
chronic diseases, such as central nervous system disorders, addiction
and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has
research facilities in Massachusetts and a commercial manufacturing
facility in Ohio.
Source: Alkermes, Inc.
Alkermes, Inc.
Eva Stroynowski, 617-583-6823
Corporate
Communications
